Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Protalix BioTherapeutics Q1 EPS $(0.05) Misses $0.03 Estimate, Sales $10.11M Miss $21.60M Estimate

Author: Benzinga Newsdesk | May 09, 2025 05:53am
Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.03 by 266.67 percent. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $10.11 million which missed the analyst consensus estimate of $21.60 million by 53.18 percent. This is a 169.82 percent increase over sales of $3.75 million the same period last year.

Posted In: PLX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist